This is a multicenter, open-label, dose escalation, Phase 1/1b study.~For Parts 1, 2, and 3 of the study, the primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with different types of hematological malignancy.~For Part 4, the primary objective is to evaluate the safety and tolerability of once-weekly dosing at the maximum-tolerated dose/ Recommended Phase 2 Dose of TG02 in combination with carfilzomib.~This study consists of four parts:~Part 1: single agent TG02 in acute leukemia patients~Part 2: single agent TG02 in multiple myeloma patients~Part 3: TG02 in combination with carfilzomib in multiple myeloma patients~Part 4: TG02 in combination with carfilzomib in carfilzomib refractory multiple myeloma patients.
This is a multicenter, open-label, dose escalation Phase 1 study.